Pharsight Corp

Pharsight — Investor Presentation (May 2005)

38 slides from Pharsight's investor presentation, May 13, 2005

  1. Slide 1: Pharsight Investor Presentation May 2005

    Slide 1: Pharsight Investor Presentation May 2005

    Exhibit 99.1 Exhibit Pharsight Investor May Shawn Cynthia 2005 O’Connor 99.1 Stephens Presentation Corporation President SVP & CFO & CEO

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking This customer expansion software, remains These development, large Quarterly date Copyright 2 Pharsight hereof, presentation pharmaceutical forward-looking atdemand, including Report of © the and 2005 scope changes sole Pharsight on contains Statements Pharsight. potential discretion

  3. Slide 3: Delivering client improvement in the clinical drug development process

    Slide 3: Delivering client improvement in the clinical drug development process

    Deliveringis… Accelerating Improving Copyright 3 Pharsight © client breakthrough 2005 client development Pharsight. product improvement time-to-market All efficiencies rights in reserved. the clinical drug development process to pharmaceutical companies by…

  4. Slide 4: Pharsight Background, Profile and Recent Progress

    Slide 4: Pharsight Background, Profile and Recent Progress

    Background Profile Business Recent – Copyright 4 Pharsight WinNonlin® Founded Headquarters East Headcount US, OTCBB: Market Pharsight® Opportunity Drug Unique 25Demonstrable consecutive Europe, Coast Financial Model and leading provider ©1995; PHST Office 2005 -Products Knowledgebase Australia to ap

  5. Slide 5: Executive Team

    Slide 5: Executive Team

    Executive Shawn President Cynthia The James Mark Hovde Mona SVP Daniel IVAX, William GloboMax, Austin-College Greg Nancy Russ VP Rene Managing Copyright Pharsight &Walt Research Global Consulting & Global Marketing Drug Wada, Lee, Bruno, Hovde Lead Sowiski Hayden Risch Associates, Merrell Weiner, O’

  6. Slide 6: Our Market Opportunity: Drug Development Productivity Decline

    Slide 6: Our Market Opportunity: Drug Development Productivity Decline

    Our Drug High Combinatorial Significant Increase Clinical $48 Productivity To process compounds, preclinical enter •drug produce or 1 2 3 Copyright 6 Pharsight Avg Genomics Rational Long, Of Only isexceed 2002 PhRMA Bain Decline approved Billion1 Market 5,000 $802M2 clinical throughput Development c

  7. Slide 7: Our Market Opportunity: Total Estimated Development Expenditure

    Slide 7: Our Market Opportunity: Total Estimated Development Expenditure

    Our Market Total $70,000 $50,000 $60,000 Estimated $30,000 2003 $0 Branded Development Copyright 7 Pharsight –Pharma 2004 2008 Phase $20,000 Pharma at ©2005 Opportunity: 34% CAGR 2005 11.0% Expenditure I –2006 8.6% Generics $10,000 of III Pharsight. Total 2007 $80,000 Spend Biotech Estimates by 2008

  8. Slide 8: Our Market Opportunity: Shifting Failure Rates and Decreasing Costs

    Slide 8: Our Market Opportunity: Shifting Failure Rates and Decreasing Costs

    Our Decreasing Impact – 1 Copyright 8 Pharsight Today Chance 25 Shifting Improving Pacific Market Years of=Research of Shifting 5% 8% © Ago FDA Opportunity: drug ability 2005 of approval =Approval failures successfully 14% Pharsight. Failure Institute to predict approval rate1 from Increasing Rates

  9. Slide 9: Software Products

    Slide 9: Software Products

    Software Products Pharsight

  10. Slide 10: Software Products Overview: Key Offerings

    Slide 10: Software Products Overview: Key Offerings

    Overview Desktop Pharsight® Drug – Copyright 10 Pharsight WinNonlin® Trial WinNonMix® Industry Computer Population (“PD”) Enterprise Software-Based Model Simulator™ Software Modeling of © Standard Knowledge Assisted Data Explorer™ Key 2005 Pharmacokinetic (“WNL™”) (“WNM™”) Software Management Commun

  11. Slide 11: WinNonlin Key Offerings

    Slide 11: WinNonlin Key Offerings

    WinNonlin® Industry Key Potential Sales – ASP Copyright 11 Pharsight WNL Used Increases Extensive One-button Maintain Provide Subscription Low-cost Distributor Software Benefits =Model $5,000 to 5.0 Standard Growth simulate upgrade ©market productivity release inside built-in 2005 in (“WNL™”) export

  12. Slide 12: Trial Simulator Key Offerings

    Slide 12: Trial Simulator Key Offerings

    Trial State-of-the-Art Key Growth Sales – ASP Copyright 12 Pharsight Minimize Intuitive, Formalize Quantify Built-in Reduce Increase Subscription Low-cost Distributor Software Benefits =Simulator™ Model $16,000 Drivers cost facility © potential uncertainty protocol-based inside risk assumptions 2005

  13. Slide 13: WinNonMix Key Offerings

    Slide 13: WinNonMix Key Offerings

    WinNonMix® Nonlinear Key Growth Sales – ASP Copyright 13 Pharsight Extensive NONMEM Built-in Estimation Maximum Increase Provide Subscription Low-cost Distributor Software Benefits =Model $7,000 Drivers upgrade report-ready Mixed © interoperability inside built-in likelihood 2005 algorithms in data

  14. Slide 14: Pharsight Knowledge Server Key Offerings

    Slide 14: Pharsight Knowledge Server Key Offerings

    Pharsight® Enterprise Key Potential Sales – ASP Copyright 14 Pharsight Tendency Dramatically Increases Reduces Supports Installed Optimize Provide PKS Subscription Software Direct Software Benefits =Model 3.0 $10,000 sales Growth upgrade © release Data long base compliance license productivity adopt

  15. Slide 15: Drug Model Explorer Key Offerings

    Slide 15: Drug Model Explorer Key Offerings

    Drug Software-Based Recently Key Potential Sales – Copyright 15 Pharsight Web-server Desktop Facilitates Enables Expand Increase Bundling Subscription Software Benefits Model Released Growth client utility more © interoperability application with more Explorer™ 2005 application Offerings and flexibl

  16. Slide 16: Software Market Acceptance Over Top 50 Pharma

    Slide 16: Software Market Acceptance Over Top 50 Pharma

    Software Over All Our 9 – 1 2 Copyright 16 Pharsight As ofTop 13 440 Pharma software the active of 1,000 active March Top 50Products Exec © Pharma2 PKSTM customers 20 50 seats 2005 applications 31, 50: Pharma2 2005 Pharsight. Market Pharmaceutical customers license as are ofare Acceptance1 March at

  17. Slide 17: Strategic Consulting Services

    Slide 17: Strategic Consulting Services

    Strategic Consulting Services Pharsight

  18. Slide 18: Strategic Consulting Services

    Slide 18: Strategic Consulting Services

    Strategicquantitative, Formal, Increases Decreases Reduces Improves Copyright 18 Pharsightfinancial Consulting drug clinical late time-to-market © 2005 stage development quality investment Pharsight. attrition Services model-based andproductivity All commercial Methodology rights decision-making res

  19. Slide 19: Strategic Consulting Services Offerings Across Development Stages

    Slide 19: Strategic Consulting Services Offerings Across Development Stages

    Preclinical (I/IIa) Candidate first-trial Scaling LEVEL OF Dose Support Strategic Copyright 19 Pharsight justification (IIb/III) (competitors, Product in-licensing design Consulting consulting Proof-of-concept ©Early 2005 in-man/ profile Phase and Pharsight. services and Services analogues) optimiza

  20. Slide 20: Strategic Consulting Services Customer Testimonial

    Slide 20: Strategic Consulting Services Customer Testimonial

    Strategic Aventis Based Evista.” Frank success.” Executive FORBES Copyright 20 Pharsight Douglas onturned Douglas Consulting that ASAP VP © 2005 simulation, ofto Aventis |Drug estimates aOctober Pharsight. computer Services Innovation Chief “We 7,that 2002 All model Scientific Customer stopped the r

  21. Slide 21: Strategic Consulting Services Potential Growth Drivers

    Slide 21: Strategic Consulting Services Potential Growth Drivers

    Strategic Industry Internal – Copyright 21 Pharsight Increased FDA Expanding Expanded Continuing Critical Factors Factors Consulting ©acceptance service 2005 scope recruitment PathPharsight. and offering Initiative Services of increasing of modeling best All Potential & rights efficiency brightest a

  22. Slide 22: Strategic Consulting Current Market Penetration

    Slide 22: Strategic Consulting Current Market Penetration

    Strategic 40% Top 30% Current Market 1 2 Copyright 22 Pharsight As Pharma 10 50 of Market Pharma2 Opportunity March Clients Consulting Exec © Penetration 2005 31, 50:2005 Pharsight. Pharmaceutical ServicesAll Market rights Executive, Penetration reserved. May– Current 2004 Clients1

  23. Slide 23: Strategic Consulting Projects Over Fiscal Year

    Slide 23: Strategic Consulting Projects Over Fiscal Year

    Strategic – Over Typical 1 2 Copyright 23 Pharsight As 13 of Pharma 25the 119 March workplans active Consulting projects Exec © Top 2005 31, clients 50: 50 engaged 2005 Pharsight. Pharma range Pharmaceutical Services during from are during All fiscal Market several active rights Fiscal Executive, ye

  24. Slide 24: Financial Overview

    Slide 24: Financial Overview

    Financial Overview Pharsight

  25. Slide 25: FY05 Results and FY06 Objectives

    Slide 25: FY05 Results and FY06 Objectives

    FY05 Fiscal Continued Y-Y 2nd Net Profitability Achieved Additional DMX Trial Copyright 25 Pharsight income consecutive revenue Simulator Accomplishments Web Yearpositive © revenue new Server 2005 of in growth 2005 $2.7 both upgrade product year Results annual Pharsight. growth million, business of

  26. Slide 26: Summary Statement of Operations

    Slide 26: Summary Statement of Operations

    Summary (‘000s Q4 FY05 Revenues Income Net EPS WASO Copyright 26 Pharsight Q4 income (common), FY04 except -(loss) basic $6,025 Statement ©(loss) FY05 2005 per from 19,226 basic $5,403 share 807 attributable Pharsight. FY04 operations of$19,055 308 Operations data) 0.03 $22,593 2,733 $All 19,122 to

  27. Slide 27: Summary Operating Results: Software Products

    Slide 27: Summary Operating Results: Software Products

    Summary Q4 FY05 OPERATING Initial Revenues 22% Gross Income PRODUCT Desktop 1,530 Copyright 27 Pharsight Q42,288 16% FY04 profit license (loss) products Operating ©Total 19% LINE 2,195 FY05 2005 $from RESULTS 450 1,530 $$REVENUES 79% Pharsight. FY04 2,769 operations 1,357 16% Results 16% 2,465 100%

  28. Slide 28: Summary Operating Results: Strategic Consulting Services

    Slide 28: Summary Operating Results: Strategic Consulting Services

    Summary STRATEGIC (‘000s) Gross Revenues Income Q4 FY05 $ Copyright 28 Pharsight 3,256 Q4FY04 profit (loss) 100% Operating ©FY05 2005 CONSULTING from $ 1,972 Pharsight. FY04 operations Results 100% –$10,515 All SERVICES Strategic rights100% reserved. Consulting $8,054 100% Q4 & FY2005 1,675 51% 780

  29. Slide 29: Quarterly Revenues

    Slide 29: Quarterly Revenues

    Quarterly Software (‘000s) $7,000 Q1 $0 Copyright 29 Pharsight FY04$6,000 Products Q2 Revenues © 2005 FY04 $5,000 Pharsight. Strategic Q3$4,000 FY04Consulting All $3,000 Q4 rights FY04 $2,000 reserved. Q1 FY05 $1,000 Q2 FY05 Q3 FY05 Q4 FY05

  30. Slide 30: Quarterly Gross Profit by Segment

    Slide 30: Quarterly Gross Profit by Segment

    Quarterly (Percentage Strategic 90% 70% Q1 0% Copyright 30 Pharsight FY04 60%Consulting Q2 Gross 50% ©of2005 FY04 Segment 40% Profit Pharsight. Q3 30% 80%FY04 Revenues) 20% Software All Q4 10%rights FY04 Products reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

  31. Slide 31: Sequential Profitability

    Slide 31: Sequential Profitability

    Sequential Profitability (‘000s) Revenues $5,000 $5,500 $6,000 Q1 $3,500 $4,000 Copyright 31 Pharsight FY04 Q2$4,500 © Profitability achieved 2005 FY04Costs Pharsight. Q3Q4 FY04 &FY04 Expenses All Q4$6,500 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

  32. Slide 32: Quarterly Operating Income

    Slide 32: Quarterly Operating Income

    Quarterly $1,500 (000s) -$ Q1 Copyright 32 Pharsight 500 1,000 1,500 2,000 FY04 $1,000 Q2 Operating © 2005 FY04 $500Pharsight. Q3 $0 Income FY04Growth All Q4 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

  33. Slide 33: Quarterly Operating Cash Flow

    Slide 33: Quarterly Operating Cash Flow

    Quarterly $2,000 (‘000s) --$500 Q1 Copyright 33 Pharsight $1,500 FY04 $1,000 $1,500 Q2 Operating © 2005 FY04 $1,000 Pharsight. Q3 Cash $500 FY04 Flow $0All Q4 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

  34. Slide 34: Summary Balance Sheet

    Slide 34: Summary Balance Sheet

    Summary March Cash ASSETS LIABILITIES A/P Deferred Redeemable Copyright 34 Pharsight &&Accrued 31, Cash Revenue Balance © March Conv 2005 Equivalents &Expenses STOCKHOLDERS’ 31, -Pharsight. Sheet Pref Long (‘000s) Stock March $Term 3,497 10,579 All 2005 6,266 126 31, rights $2004 $2,518 2005 6,164 5

  35. Slide 35: Equity Structure

    Slide 35: Equity Structure

    Equity (All Preferred Common PIPE – Copyright 35 Pharsight Automatically At Warrants Series 1.8 Preferred Dividend Conversion: Upon Redemption: share election million Financing Structure close AShares Equivalent data © 1.8 exercisable conversion rights: 2005 of Units of million as at 6/02 public upo

  36. Slide 36: Current Summary

    Slide 36: Current Summary

    Current Summary Increasing Continuing All Financially Copyright 36 Pharsight Support Pharma © Mindshare Stable Pharsight Our 2005 Market Drive & Pharsight. Healthy Investment for Towards Trends Quantitative-Based All Business Look Expansion rights in Sales, Favorable… Model… reserved. Marketing of M

  37. Slide 37: Proprietary Notices

    Slide 37: Proprietary Notices

    Proprietary Notices No Model All Copyright 37 Pharsight part contents other ExplorerTM, ofbrand Corporation. © this Notice Copyright 2005 document andPharsight. product DMXTM, WinNonlin®, ©2005 maynames All be Pharsight Trial rights reproduced are SimulatorTM WinNonMix® trademarks reserved. Corporat

  38. Slide 38: Pharsight

    Slide 38: Pharsight

    Pharsight

Source: SEC EDGAR · 8-K filed May 13, 2005

More decks from Pharsight Corp